Interferon regulatory factor 1 mediates ROS-dependent release of NETs in LPS-induced mouse pneumonia by interacting

Yandan Wei1, Wei Fu1, Yanxia Liu2

  • 1Department of PICU, Huadu Maternal and Child Health Hospital of Guangzhou, Guangzhou, Guangdong Province, PR China.

Autoimmunity
|July 16, 2026
PubMed

Insights

Interferon regulatory factor 1 (IRF1) drives neutrophil extracellular trap (NET) release in pediatric pneumonia by promoting mitochondrial dysfunction and reactive oxygen species (ROS) production. Targeting the IRF1-matrix metalloproteinase 9 (MMP9) axis may offer therapeutic strategies for lung injury.

Area of Science:

  • Immunology
  • Cell Biology
  • Pulmonology

Background:

  • Interferon regulatory factor 1 (IRF1) is linked to reactive oxygen species (ROS)-dependent neutrophil extracellular trap (NET) release in acute lung injury.
  • The specific role of IRF1 in mitochondrial dysfunction-driven NETosis in pediatric pneumonia is not understood.

Purpose of the Study:

  • To investigate the role of IRF1 in mitochondrial dysfunction and NETosis in pediatric pneumonia.
  • To elucidate the underlying mechanisms involving ROS and matrix metalloproteinase 9 (MMP9).

Main Methods:

  • Neutrophils were isolated from pediatric pneumonia patients and mice.
  • IRF1 expression, ROS levels, mitochondrial function, and NETosis markers were quantified.
  • In vivo mouse models of pneumonia were used to assess lung injury.
  • IRF1-MMP9 interaction was studied using bioinformatics, co-immunoprecipitation, and immunofluorescence.

Main Results:

  • IRF1 was upregulated in neutrophils from pediatric pneumonia patients, correlating with increased ROS, mitochondrial dysfunction, and NETosis.
  • IRF1 knockdown reduced ROS-driven NETosis in vitro.
  • MMP9 overexpression reversed the protective effects of IRF1 deficiency, exacerbating lung injury in vivo.

Conclusions:

  • IRF1 plays a critical role in promoting mitochondrial dysfunction and NETosis in pediatric pneumonia.
  • The IRF1-MMP9 interaction is a key pathway in the pathogenesis of pneumonia-related lung injury.
  • Modulating the IRF1-MMP9 axis could be a therapeutic target for pediatric pneumonia.